These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 38166148)

  • 21. The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data.
    Li BX; Wang YQ; Yi YY; Zhou N; Lv ZX; Ma R; Li X; Yuan N
    BMC Public Health; 2024 May; 24(1):1309. PubMed ID: 38745323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
    Berkemeier F; Whaley C; Robinson JC
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1310-1317. PubMed ID: 31778624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis.
    Huang C; Ung COL; Wushouer H; Bai L; Li X; Guan X; Shi L
    Int J Health Policy Manag; 2022 Aug; 11(8):1489-1495. PubMed ID: 34273922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consistency of new drug pricing in Korea: Bridging variations among personnel in price negotiations.
    Kwon HY; Kim J
    Health Policy; 2020 Sep; 124(9):965-970. PubMed ID: 32660816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China.
    Ling K; Qin H; Feng Y; Che H; Ding J; Li W
    Front Public Health; 2022; 10():1062736. PubMed ID: 36504948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives.
    Hernandez I; Cousin EM; Wouters OJ; Gabriel N; Cameron T; Sullivan SD
    J Manag Care Spec Pharm; 2024 Aug; 30(8):762-772. PubMed ID: 38905356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Comparative Analysis of International Drug Price Negotiation Frameworks: An Interview Study of Key Stakeholders.
    Syversen ID; Schulman K; Kesselheim AS; Feldman WB
    Milbank Q; 2024 Dec; 102(4):1004-1031. PubMed ID: 39289915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Negotiating antiretroviral drug prices: the experience of the Andean countries.
    Seoane-Vazquez E; Rodriguez-Monguio R
    Health Policy Plan; 2007 Mar; 22(2):63-72. PubMed ID: 17299024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
    Rome BN; Nagar S; Egilman AC; Wang J; Feldman WB; Kesselheim AS
    JAMA Health Forum; 2023 Jan; 4(1):e225218. PubMed ID: 36705916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrating Price Benchmarks and Comparative Clinical Effectiveness to Inform the Medicare Drug Price Negotiation Program.
    Sullivan SD; Wouters OJ; Cousin EM; Kirihennedige AS; Hernandez I
    Value Health; 2024 Oct; 27(10):1348-1357. PubMed ID: 39154910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study.
    Cai L; Tao T; Li H; Zhang Z; Zhang L; Li X
    J Glob Health; 2022 Dec; 12():11016. PubMed ID: 36527382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis.
    Vokinger KN; Hwang TJ; Carl DL; Laube Y; Ludwig WD; Naci H; Kesselheim AS
    Lancet Oncol; 2022 Apr; 23(4):514-520. PubMed ID: 35271804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada.
    Rawson NSB; Stewart DJ
    Clinicoecon Outcomes Res; 2024; 16():437-445. PubMed ID: 38812711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations.
    DiStefano MJ; Levy JF; Odouard IC; Anderson GF
    Value Health; 2023 Nov; 26(11):1618-1624. PubMed ID: 37689264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions.
    Sullivan SD
    Value Health; 2023 Mar; 26(3):394-399. PubMed ID: 36503034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
    Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
    PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
    Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
    JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationships between developmental strategies for additional indications and price revisions for anticancer drugs in Japan.
    Maeda H; Okabe A; Sakakura K; Ng DB; Akazawa M
    BMC Health Serv Res; 2021 Dec; 21(1):1329. PubMed ID: 34895223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland.
    Michaeli DT; Mills M; Kanavos P
    Appl Health Econ Health Policy; 2022 Sep; 20(5):757-768. PubMed ID: 35821360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.